Leukemia & Lymphoma Breakthroughs in 2025

In 2025, blood cancer treatment has progressed from traditional chemo to bispecific antibodies and CAR-T cell therapies, offering higher remission rates and personalized care.

Key 2025 Developments:

  • Epcoritamab: FDA-approved for relapsed DLBCL

  • Teclistamab: Strong efficacy in relapsed multiple myeloma

  • CAR-T therapies (Kymriah, Yescarta): Over 60% response in difficult leukemia/lymphoma cases

Section

Best Candidates:

2025 Insight:

“Epcoritamab achieved a complete response in 39% of patients with relapsed DLBCL.”
Source: Blood Cancer Journal, 2025

 Best Candidates:

  • Relapsed or treatment-resistant patients

  • Those ineligible or unresponsive to chemotherapy

  • Tumors with CD20/CD3 expression

📚 References:

  • Efficacy of Epcoritamab in B-cell Lymphoma – Blood Cancer Journal, 2025

  • Long-Term Outcomes of CAR-T in Adult ALL – ASH Annual Meeting, 2025

  • Teclistamab Response Rates in Relapsed Myeloma – Nature Hematology, 2025